Overview

A Randomized, Double-Blind, Placebo-Controlled Study of Liafensine in Patients With Treatment-Resistant Depression

Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This study will be conducted as a randomized, double-blind, placebo-controlled, multi-center Phase 2b study. Approximately 180 subjects with treatment resistant depression who meet all eligibility criteria will be enrolled.
Phase:
Phase 2
Details
Lead Sponsor:
Denovo Biopharma LLC